QGEN vs SYRE
Qiagen N.V. vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
72
Buy
| Metric | QGEN | SYRE |
|---|
| AI Score |
71
|
72
|
| Price |
$42.98
|
$103.56
|
| P/E Ratio |
22.03×
|
-53.14×
|
| ROE |
11.2%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
61.8%
|
0.0%
|
| Debt / Equity |
0.49×
|
0.00×
|
| Dividend Yield |
6.1%
|
0.0%
|
| RSI (14) |
58.7
|
54.6
|
| Beta |
0.62
|
3.026
|
| Expected Upside |
+1.9%
|
—
|
AI Committee View
Current Innellis committee reasoning for QGEN versus SYRE.
SYRE leads by 1 points.
SYRE scores 72/100 (Buy) versus QGEN at 71/100 (Buy).
QGEN Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
SYRE Committee View
100% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical